Alaunos Therapeutics, Inc. short interest in 2022
In 2022, Alaunos Therapeutics, Inc.'s disclosed short interest ran from 16.32% of shares outstanding on 14 Jan 2022 to 12.06% on 30 Dec 2022, a change of -4.26 percentage points. The year's high was 16.64% on 13 May 2022 and its low 12.06% on 30 Dec 2022, averaging 14.40% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.42 days on 15 Nov 2022. Full history: Alaunos Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 16.32% (14 Jan 2022)
- End of year
- 12.06% (30 Dec 2022)
- Change
- -4.26 pp
- High
- 16.64% (13 May 2022)
- Low
- 12.06% (30 Dec 2022)
- Average
- 14.40%
- Highest days to cover
- 27.42 (15 Nov 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 16.32% | 17.93 | |
| 14 Apr 2022 | 15.83% | 19.03 | 10-K filed, results (8-K) |
| 29 Apr 2022 | 15.65% | 13.16 | |
| 13 May 2022 | 16.64% | 11.43 | |
| 31 May 2022 | 16.63% | 20.10 | 10-Q filed, results (8-K) |
| 15 Jun 2022 | 16.31% | 6.16 | |
| 30 Jun 2022 | 13.23% | 5.47 | |
| 15 Jul 2022 | 13.36% | 15.73 | |
| 29 Jul 2022 | 13.95% | 24.84 | |
| 15 Aug 2022 | 13.43% | 14.41 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 13.44% | 9.46 | |
| 15 Sep 2022 | 12.95% | 3.46 | |
| 30 Sep 2022 | 13.45% | 4.32 | |
| 14 Oct 2022 | 13.59% | 11.56 | |
| 31 Oct 2022 | 14.88% | 26.02 | |
| 15 Nov 2022 | 14.66% | 27.42 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 14.47% | 13.12 | |
| 15 Dec 2022 | 12.81% | 18.16 | |
| 30 Dec 2022 | 12.06% | 12.27 |
See also: Alaunos Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.